Australia: Federal Court decides isolated DNA is patentable subject matter

Key Points:

Isolated naturally occurring DNA or RNA sequences can be patentable under Australian law.

The Federal Court has clarified the position of so-called "gene patents" under Australian law. Cancer Voices Australia v Myriad Genetics Inc [2013] FCA 65 is the first Australian decision to consider the patentability of isolated naturally occurring DNA or RNA sequences. The case confirms that, when isolated from their natural environment, these sequences can be patentable under Australian law. The case provides welcome certainty, although public debate is likely to continue.

The BRCA1 gene and the patent

Whether genetic material ought to be patentable has long been the subject of debate both in Australia and overseas. This case related to certain claims of an Australian patent owned by US based molecular diagnostics company Myriad Genetics Inc. Myriad's patent relates to the BRCA1 gene, which is what is known as a breast and ovarian cancer disposing gene. A mutation of the BRCA 1 gene results in an increased risk of breast and ovarian cancer and the gene is therefore useful in diagnostic testing. The claims in dispute related to "naturally occurring" nucleic acid (either DNA or RNA) that has been "isolated" from the cellular environment in which it naturally exists.

Cancer Voices Australia (a national network of cancer advocacy groups) and breast cancer survivor Yvonne D'Arcy challenged the validity of the claims relating to the isolated genetic material, on the sole basis that the isolated genetic material was not proper subject matter for a patent. The applicants did not rely on any of the other available grounds for challenging the validity of a patent.

Isolated DNA and RNA

While "human beings and biological processes for their production" are not patentable, the Patents Act does not include any specific prohibition on the grant of a patent for an isolated DNA or RNA sequence. The applicants did not argue that DNA or RNA were biological processes for the production of human beings. Instead, they argued that the isolated genetic sequences did not satisfy the "manner of manufacture" requirement for patentable subject matter. This requirement distinguishes patentable inventions from "mere discoveries", which are not patentable under Australian patent law.

The respondents argued that each of the disputed claims was valid because the isolated nucleic acid found in human cells differs from the isolated nucleic acid claimed in the patent. In particular, they argued that the process of isolating, at least, DNA sequences necessarily involved breaking covalent bonds. Although not accepting this general proposition, Justice Nicholas accepted that the isolated genetic material was different from that genetic material existing in its context in the human body, holding that "naturally occurring DNA and RNA are not within the scope of any of the disputed claims and could never, at least not until they had been isolated, result in the infringement of any such claim."

The "manner of manufacture" requirement

According to section 18(1)(a) of the Patents Act, to be patentable an invention must be a "manner of manufacture". The term "manner of manufacture" is a reference to an old English statute and is not defined in the Patents Act. Australian courts have resisted giving the term a precise definition in order to allow the law to adapt to advances in technology.

The leading authority on the meaning of "manner of manufacture" is the NRDC1decision in which the High Court held that a new method for using known chemicals to eradicate weeds from crops was a "manner of manufacture" because:

  • it resulted in an artificially created state of affairs; and
  • its effect had economic significance.

As there was no dispute in this case as to economic significance, the only issue for Justice Nicholas to decide was whether the isolation of the nucleic acid described in the claims was "an artificially created state of affairs".

The decision

Justice Nicholas held that an isolated nucleic acid constitutes an "artificially created state of affairs in the sense those words should be understood in the present context". This was so because the nucleic acid is not found in the body in its isolated form, and because the naturally occurring nucleic acid does not exist outside the body without human intervention. He identified the following key considerations:

  • the High Court deliberately used expansive language in the NRDC case, so as not to fetter changing understandings of technology;
  • "isolated" nucleic acid is the product of human intervention which involves the extraction and purification of the nucleic acid found inside the cell; and
  • the isolation of a particular DNA sequence can require immense research and intellectual effort and failing to acknowledge the result of this effort and expense as a manner of manufacture would lead to "very odd results".

Justice Nicholas considered his finding consistent with decisions of the Australian Patents Office on the patentability of isolated DNA and with European Union law which specifically provides that an element isolated from the body, including the sequence or partial sequence of a gene, "may constitute a patentable invention, even if the structure of that element is identical to that of a natural element". He also noted that the equivalent litigation to the Myriad Genetics case in the US is on appeal to the Supreme Court, and is, in any event, not directly relevant because of differences in US law.

Recent amendments to the Patents Act

Although they were not authoritative in relation to his decision, Justice Nicholas gave consideration to the recent law reform and parliamentary enquiries and reports relating to gene patenting. Justice Nicholas noted widely expressed views that it would not now be appropriate from a social, political or economic perspective to pass laws making genetic material unpatentable on a per se basis.

Justice Nicholas also reviewed the history of recent amendments to the Patents Act (including the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)). Section 119C of the Patents Act now provides a defence to patent infringement for "experimental use". This overcomes one argument commonly advanced against the patentability of isolated DNA sequences, specifically "the impact that patents for such materials may have on future research into previously undiscovered genetic mutations and research and the development of new diagnostic and therapeutic technologies that may only take place using patented biological materials."

He also noted the new section 7A in the Patents Act, imposing a more onerous requirement for a patented invention to be "useful". It is considered that this requirement may have an impact on attempts to patent certain shorter genetic sequences called expressed sequence tags or ESTs, the patentability of which has been the subject of particular debate.


While this case does clarify the law in Australia relating to the patentability of naturally occurring genetic material, it is important to note two limitations on the case's influence.

First, the case was argued solely on the question of whether isolated "naturally occurring" genetic material can be subject matter for a patent. None of the other requirements for patentability were addressed. Every time a patent application seeks to claim isolated genetic material, it will remain subject to all of the other requirements for patentability.

In particular, the case did not address whether the isolated DNA or RNA was sufficiently inventive to warrant patentability. All patents remain subject to the (often onerous requirement) of "inventive step" or "non-obviousness", and those requirements will continue to impose restraints on patentability.

Secondly, only the claims of the patent relating to the genetic material itself were challenged. As the patent had other claims covering diagnostic methods, Myriad would still have had a patent monopoly in relation to its methods even if the challenge had been successful. The ethical question of whether naturally occurring genetic material ought to be patentable per se may therefore be proven to be somewhat limited in its practical consequence.

A similar past question, now clearly resolved in the affirmative in Australia, was whether methods of treatment for the human body are patentable. When that question was unresolved, patent claims were often creatively drafted to avoid this potential difficulty, with the result that the ethical question involved was, largely, rendered theoretical.

The same considerations apply in relation to genetic material as patent subject matter; in the context of the Australian patent system overall, this clarification seems unlikely to have an impact on access to medical treatment.

It remains to be seen whether the applicants seek to appeal this decision. Whether or not an appeal occurs, the debate is likely to continue, with Cancer Voices Australia now calling upon the public to sign a petition to the Australian Parliament.

You might also be interested in ...


1 National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252.

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.